BTAI BioXcel Therapeutics Inc
Company Analysis
Latest News
BioXcel Therapeutics suspended from Nasdaq, moves to Pink Market after bankruptcy
Nasdaq suspended trading of BioXcel Therapeutics' common stock on September 8, 2026. The action follows the company's Chapter 11 bankruptcy filing on August...
🔴 BioXcel Therapeutics is trading 37.11% down today amid Chapter 11 bankruptcy filing
BioXcel Therapeutics is trading at $0.07, down 37.11%, as it faces Nasdaq trading suspension and an expected move to the OTC Pink Limited Market on September...
🔴 BioXcel Therapeutics is trading 22.13% down today amid Chapter 11 filing and Nasdaq delisting
BioXcel Therapeutics is trading 22.13% down at $0.09 after continued pressure from its August 27, 2026 Chapter 11 filing and Nasdaq’s August 31 delisting...
🔴 BioXcel Therapeutics is trading 17.62% down in pre-market amid Chapter 11 filing and Nasdaq delisting
BioXcel Therapeutics is trading at $0.10 (-17.62%) in pre-market amid continued pressure from its August 27, 2026 Chapter 11 filing and Nasdaq’s subsequent...
🔴 BioXcel Therapeutics is trading 5.6% down in after-hours trading amid Chapter 11 filing overhang
BioXcel Therapeutics is trading 5.6% down at $0.11 after declining from the September 3, 2026 regular-session close of $0.12, amid overhang from the company’s...
🟢 BioXcel Therapeutics is trading 13% up today amid a biotech-sector rebound
BioXcel Therapeutics is trading 12.9% up now at $0.12, with the move occurring during a broader biotech rebound. - The biotech sector ETF is up 2.75%, while...
BioXcel Therapeutics Dropped from S&P TMI Index
BioXcel Therapeutics, Inc. exited the S&P TMI Index. This follows the company's recent Chapter 11 bankruptcy filing and plans to sell its assets. Earlier in...
🟢 BioXcel Therapeutics is trading 8.4% up today after Teva proposed asset acquisition
BioXcel Therapeutics is trading at $0.12 (+8.41%) after Teva proposed acquiring substantially all assets in its Chapter 11 asset-sale process. - The proposal...
🟢 BioXcel Therapeutics is trading 30% up in pre-market amid proposed Teva asset sale
BioXcel Therapeutics is trading at $0.14 (+30.00%) after continued volatility surrounding its August 27, 2026 Chapter 11 filing and proposed sale of...
🟢 BioXcel Therapeutics is trading 9.63% up in after-hours trading after Chapter 11, proposed Teva asset sale
BioXcel Therapeutics is trading 9.63% up in after-hours trading at $0.12 after continued volatility following its August 27, 2026 Chapter 11 filing and...
🔴 BioXcel Therapeutics is trading 11% down today after August 27, 2026 Chapter 11 filing
BioXcel Therapeutics is trading at $0.12 (-10.51%) after continued selling following its August 27, 2026 Chapter 11 filing and proposed asset sale. • The...
🟢 BioXcel Therapeutics is trading 13% up today on biotech-sector gains
BioXcel Therapeutics is trading 13% up at $0.15, primarily as biotech stocks gain while investors also trade the company’s restructuring situation. - The...
🔴 BioXcel Therapeutics is trading 5.8% down in pre-market after Chapter 11 filing and delisting notice
BioXcel Therapeutics is trading at $0.13, down 5.77% in pre-market after its August 27, 2026 Chapter 11 filing and related restructuring developments. •...
BTAI Secures $77.25M Debtor-in-Possession Financing, Faces Nasdaq Delisting
Following its Chapter 11 bankruptcy filing on August 27, 2026, BioXcel Therapeutics (BTAI) has entered into a debtor-in-possession (DIP) credit agreement to...
🔴 BioXcel Therapeutics is trading 20% down today after Nasdaq delisting confirmation following Chapter 11 bankruptcy
BioXcel Therapeutics is trading 19.96% down now at $0.13 after Nasdaq confirmed delisting following its voluntary Chapter 11 bankruptcy filing. - The...
BioXcel's Nasdaq Exit and Teva Fire Sale: What Will Shareholders Actually Recover From Bankruptcy?
Shares of BioXcel Therapeutics collapsed to $0.13 — an 18.9% single-day drop and a staggering 83% plunge from $0.78 just five trading days earlier — after...
BioXcel Therapeutics to delist from Nasdaq, names Teva as lead bidder
Nasdaq notified BioXcel Therapeutics Inc. on August 31, 2026, that its common stock will be delisted. This action follows the company’s voluntary Chapter 11...
🔴 BioXcel Therapeutics is trading 13.14% down in pre-market after Chapter 11 filing and proposed Teva sale
BioXcel Therapeutics is trading 13.14% down now at $0.14 after its August 27, 2026 Chapter 11 filing and proposed sale of substantially all assets to Teva. -...
🔴 BioXcel Therapeutics is trading 5% down in after-hours trading after Chapter 11 filing
BioXcel Therapeutics is trading 5.04% down at $0.15 after its August 27, 2026 Chapter 11 filing and proposed sale of substantially all assets to Teva. •...
🔴 BioXcel Therapeutics is trading 16.8% down today after Chapter 11 filing
BioXcel Therapeutics is trading at $0.15, with a -16.81% change, after its August 27, 2026 Chapter 11 filing and proposed sale of substantially all assets to...